CXCL12 is produced by bone marrow stromal cells in T-ALL patients [154] and has been recently demonstrated to be involved in PI3K/Akt activation and drug-resistance in T-ALL cells [155]. This evidence concerns the gene CXCL12 and acute lymphoblastic leukemia.